2024
Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight
Kopp P, Yang C, Yang H, Katz J, Paltiel A, Hunter D, Callahan L, Mihalko S, Newman J, DeVita P, Loeser R, Miller G, Messier S, Losina E. Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight. Arthritis Care & Research 2024, 76: 1018-1027. PMID: 38450873, DOI: 10.1002/acr.25323.Peer-Reviewed Original ResearchBody mass indexUsual careQuality-adjusted life yearsHealth educationIncremental cost-effectiveness ratioKnee osteoarthritisKnee OAGroup-based health educationWestern Ontario and McMaster Universities Osteoarthritis Index pain scoreLifetime costsOA careE programCost-effectiveIncremental cost-effectivenessFunctional limitationsIncreased lifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioLife yearsMass indexPain reductionSocietal perspectiveCohort characteristicsKneeExercise
2023
Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price
Amick A, Eskibozkurt G, Hosek S, Flanagan C, Landovitz R, Jin E, Wilson C, Freedberg K, Weinstein M, Kazemian P, Paltiel A, Ciaranello A, Neilan A. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases 2023, 78: 402-410. PMID: 37823865, PMCID: PMC10874274, DOI: 10.1093/cid/ciad566.Peer-Reviewed Original ResearchPre-exposure prophylaxisHIV incidenceRisk of HIVOral PrEPAnnual screeningHuman immunodeficiency virus (HIV) pre-exposure prophylaxisOral HIV pre-exposure prophylaxisHIV pre-exposure prophylaxisIncremental cost-effectiveness ratioHIV RNA levelsYoung menCost-effectiveness ratioAnnual HIVHigher discontinuationPrEP retentionAntiretroviral therapyDrug pricesHIV careLow adherenceLifetime horizonNew infectionsHIVIncidencePrEPRNA levelsCost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity
Kostic AM, Leifer VP, Selzer F, Hunter DJ, Paltiel AD, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, Losina E. Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity. Arthritis Care & Research 2023, 75: 1752-1763. PMID: 36250415, PMCID: PMC10375659, DOI: 10.1002/acr.25044.Peer-Reviewed Original ResearchConceptsLaparoscopic sleeve gastrectomyClass III obesityIncremental cost-effectiveness ratioTotal knee replacementQuality-adjusted life expectancyWeight loss interventionProbabilistic sensitivity analysesKnee replacementNonsurgical weight loss interventionsLong-term clinical benefitWeight lossKnee osteoarthritis patientsWeight loss strategiesHealth care sector perspectiveOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioWeight loss/Gastric bypassSleeve gastrectomyPrimary outcomeLoss interventionOsteoarthritis patientsClinical benefitHigher complications
2022
Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France
Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, Paltiel A, Deuffic‐Burban S. Cost‐effectiveness of hepatitis C virus test‐and‐treat and risk reduction strategies among men who have sex with men living with HIV in France. Journal Of The International AIDS Society 2022, 25: e26035. PMID: 36451286, PMCID: PMC9712801, DOI: 10.1002/jia2.26035.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusIncremental cost-effectiveness ratioHigh-risk groupHepatitis C virusHCV screeningRisk reduction strategiesHCV infectionYearly screeningHepatitis C Virus TestRisk reductionHCV screening practicesNew HCV infectionsHigh-risk individualsRisk reduction interventionsCost-effectiveness ratioCost-effective dependingImmunodeficiency virusC virusScreening practicesLifetime horizonScreening frequencyVirus testReduction interventionsRisk behaviorsBehavioral interventionsDoes gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis
Bensen G, Rogers A, Leifer V, Edwards R, Neogi T, Kostic A, Paltiel A, Collins J, Hunter D, Katz J, Losina E. Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. Osteoarthritis And Cartilage 2022, 31: 279-290. PMID: 36414225, PMCID: PMC9892279, DOI: 10.1016/j.joca.2022.07.013.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioKnee osteoarthritisUsual careNociplastic painCumulative quality-adjusted life yearsMore quality-adjusted life yearsNeuropathic pain syndromesDirect medical costsOsteoarthritis Policy ModelLifetime direct medical costsCost-effectiveness ratioCost-effectiveness analysisOA carePainDETECT questionnairePain syndromeCost‐Effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
Williams EE, Katz JN, Leifer VP, Collins JE, Neogi T, Suter LG, Levy B, Farid A, Safran‐Norton C, Paltiel AD, Losina E. Cost‐Effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear. ACR Open Rheumatology 2022, 4: 853-862. PMID: 35866194, PMCID: PMC9555200, DOI: 10.1002/acr2.11480.Peer-Reviewed Original ResearchArthroscopic partial meniscectomyIncremental cost-effectiveness ratioCost-effectiveness ratioInitial physical therapyOptional surgeryPhysical therapyPartial meniscectomyMeniscal tearsImmediate surgeryTreatment optionsHigh incremental cost-effectiveness ratioConcomitant meniscal tearsOsteoarthritis Research (MeTeOR) trialDegenerative meniscal tearsOsteoarthritis Policy ModelMonte Carlo microsimulationProbabilistic sensitivity analysesBase-case assumptionsSurgery efficacyPersistent painKnee osteoarthritisPost surgeryTreatment strategiesSurgery strategySurgeryCost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2022, 175: 479-489. PMID: 35099992, PMCID: PMC9087297, DOI: 10.7326/m21-1548.Peer-Reviewed Original ResearchConceptsCAB-LAHIV preexposure prophylaxisCost-effectiveness analysisPreexposure prophylaxisHigh riskNational InstituteIncremental cost-effectiveness ratioCost-effectiveness ratioBase-case analysisHealth care systemEunice KennedyInjectable cabotegravirPrEP retentionOral PrEPHIV PrEPHIV incidenceBlood InstituteDisoproxil fumarateNational HeartChild healthSide effectsTransgender womenInfectious diseasesPrEPQALY
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costsClinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Annals Of Internal Medicine 2021, 174: 803-810. PMID: 33683930, PMCID: PMC9317280, DOI: 10.7326/m21-0510.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Antigen testingHome testingSARS-CoV-2 antigen testingIncremental cost-effectiveness ratioSARS-CoV-2 transmissionCost-effectiveness ratioBase-case analysisRapid testingPrevention guidanceDeath avertedDisease progressionInpatient careCommunity transmissionOutcome estimatesTesting interventionsViral transmissionDisease controlInfectionNumber of personsCumulative infectionsNational containment strategyWarrants considerationU.S. populationDeath
2020
Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States
Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases 2020, 73: e1927-e1935. PMID: 32730625, PMCID: PMC8492162, DOI: 10.1093/cid/ciaa1061.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHIV transmissionAge 15High-risk young menAdolescent Medicine Trials NetworkAntiretroviral therapy initiationIncremental cost-effectiveness ratioNew HIV infectionsLife expectancyYoung menCost-effectiveness ratioFrequent HIVCD4 countHIV screeningTherapy initiationHIV infectionClinical outcomesHIV incidenceClinical benefitFrequent screeningART costsHIVAge 30Trials NetworkYMSMComparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2020, 172: 583-590. PMID: 32150602, PMCID: PMC7217721, DOI: 10.7326/m19-3478.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness analysisFair priceCost-effectiveness ratioBase-case analysisJustifiable priceSocietal willingnessComparative pricingHealth care sectorPricesTime horizonEnd-stage renal diseaseCases of ESRDQALYDemand PrEPCare sectorEconomic savingsHIV preexposure prophylaxisSensitivity analysisCostPreexposure prophylaxisLife effectsHorizonPricingDiscount
2019
Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector
Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, Paltiel AD, Freedberg KA, Reddy KP. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector. PLOS ONE 2019, 14: e0218890. PMID: 31265470, PMCID: PMC6605662, DOI: 10.1371/journal.pone.0218890.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLife expectancySmear microscopyXpert MTB/RIFHIV-negative adultsPeripheral healthcare settingsMTB/RIFPrimary healthcare facilitiesSputum smear microscopyCost-effectiveness ratioCost-effectiveness analysisPresumptive tuberculosisTB diagnosisTB prevalenceTruenatMicroscopy centresXpertBudget impactRifampicin resistanceDiagnostic strategiesTuberculosisTB detectionHealthcare settingsDiagnostic sensitivityNovel molecular assayCost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDietCost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomes
2018
2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector
Lee D, Kumarasamy N, Resch S, Sivaramakrishnan G, Mayer K, Tripathy S, Paltiel A, Freedberg K, Reddy K. 2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector. Open Forum Infectious Diseases 2018, 5: s582-s582. PMCID: PMC6254532, DOI: 10.1093/ofid/ofy210.1656.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioPublic healthcare facilitiesLife expectancyXpert MTB/RIFHIV-negative patientsPeripheral healthcare settingsHealthcare facilitiesBudgetary impact analysisMTB/RIFDiagnostic test costsSputum smear microscopyCost-effectiveness ratioMulti-way sensitivity analysesTB outcomesTB diagnosisPoint of careTruenatSmear microscopyXpertBudget impactTuberculosis diagnosticsDiagnostic strategiesHealthcare expendituresHealthcare settingsRifampin resistanceCost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement
Smith KC, Paltiel AD, Yang HY, Collins JE, Katz JN, Losina E. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement. Osteoarthritis And Cartilage 2018, 26: 1495-1505. PMID: 30092263, PMCID: PMC6202236, DOI: 10.1016/j.joca.2018.07.014.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesFinancial incentivesOne-way sensitivity analysesDeterministic sensitivity analysesCost-effectiveness ratioSensitivity analysisCost-effectiveness outcomesOsteoarthritis Policy ModelEfficacy of THCKnee replacement recipientsPolicy modelLife yearsTelephonic health coachingQALYHealthcare perspectiveThe cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India. Journal Of The International AIDS Society 2018, 21: e25085. PMID: 29603882, PMCID: PMC5878415, DOI: 10.1002/jia2.25085.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careAntiretroviral therapyTenofovir disoproxil fumarateHIV infectionRecent guidelinesFirst-line antiretroviral therapyFirst-line HIV treatmentLifetime incremental cost-effectiveness ratioART-naive patientsDolutegravir-based regimenDTG-based regimenFirst-line treatmentClinical trial dataCost-effectiveness ratioLifetime care costsInitial therapyVirologic suppressionCD4 countHIV diseaseRegimen costsDisoproxil fumarateHIV treatmentAIDS complicationsCare costsThe cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil
Luz PM, Osher B, Grinsztejn B, Maclean RL, Losina E, Stern ME, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, Walensky RP, Veloso VG, Paltiel AD. The cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Journal Of The International AIDS Society 2018, 21: e25096. PMID: 29603888, PMCID: PMC5878414, DOI: 10.1002/jia2.25096.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHIV infectionTransgender womenPrEP effectivenessHigh riskMedical costsPre-exposure prophylaxis programHIV pre-exposure prophylaxisAnnual HIV incidenceUniversal ART accessPre-exposure prophylaxisHIV testing frequencyDirect medical costsHigh-risk MSMLife expectancyHIV infection riskUndiscounted life expectancyCost-effectiveness ratioYears of lifeUnited States dollarsHIV careHIV incidenceMean ageProphylaxis programART accessCost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation
Losina E, Usiskin I, Smith S, Sullivan J, Smith K, Hunter D, Messier S, Paltiel A, Katz J. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation. Osteoarthritis And Cartilage 2018, 26: 641-650. PMID: 29481917, PMCID: PMC6334297, DOI: 10.1016/j.joca.2018.02.898.Peer-Reviewed Original Research
2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men